Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does MITOXANTRONE Cause Malignant neoplasm progression? 70 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 70 reports of Malignant neoplasm progression have been filed in association with MITOXANTRONE (mitoXANTRONE). This represents 1.7% of all adverse event reports for MITOXANTRONE.

70
Reports of Malignant neoplasm progression with MITOXANTRONE
1.7%
of all MITOXANTRONE reports
25
Deaths
23
Hospitalizations

How Dangerous Is Malignant neoplasm progression From MITOXANTRONE?

Of the 70 reports, 25 (35.7%) resulted in death, 23 (32.9%) required hospitalization, and 2 (2.9%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for MITOXANTRONE. However, 70 reports have been filed with the FAERS database.

What Other Side Effects Does MITOXANTRONE Cause?

Febrile neutropenia (668) Off label use (368) Neutropenia (296) Drug ineffective (293) Thrombocytopenia (256) Sepsis (240) Pyrexia (214) Product use in unapproved indication (177) Disease progression (173) Acute myeloid leukaemia (167)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which MITOXANTRONE Alternatives Have Lower Malignant neoplasm progression Risk?

MITOXANTRONE vs MITRAGYNINE\HERBALS MITOXANTRONE vs MIZORIBINE MITOXANTRONE vs MOBOCERTINIB MITOXANTRONE vs MOCLOBEMIDE MITOXANTRONE vs MODAFINIL

Related Pages

MITOXANTRONE Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression MITOXANTRONE Demographics